A machine learning tool for identifying non-metastatic colorectal cancer in primary care

The performance of FIT-based and other risk prediction models for colorectal neoplasia in symptomatic patients: a systematic review

“…All included studies were of an observational study design, with 21 cross-sectional studies, 19 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 17 retrospective studies, 18 , 30 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 15 prospective studies, 39 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 and eight case–control studies. 62 , 75 , 76 , 77 , 78 , 79 , 80 One study design was unclear, as it was an abstract only. 81…”

“…Settings were primary care (n = 21), 30 , 31 , 35 , 47 , 50 , 51 , 52 , 53 , 54 , 56 , 59 , 62 , 64 , 66 , 68 , 71 , 73 , 77 , 78 , 80 primary and secondary care (n = 12), 18 , 19 , 30 , 33 , 34 , 49 , 60 , 63 , 65 , 67 , 72 secondary care (n = 24), 29 , 32 , 36 , 37 , 38 , 39 , 41 , 42 , 43 , 44 , 46 , 48 , 55 , 57 , 58 , 61 , 62 , 69 , 70 , 74 , 75 , 76 , 79 , 82 secondary and tertiary care (n = 3), 27 , 28 , 40 and tertiary care (n = 1). 45 One study was unclear regarding the setting.…”

“…81 Databases or registries were used in 17 studies. 30 , 47 , 48 , 50 , 51 , 52 , 53 , 54 , 56 , 60 , 77 , 78 , 79 , 80 , 82 , 83 , 84 …”

“…One study examined patients from two different countries: Scotland and Spain. 18 A further 24 studies assessed patients from the UK, 30 , 31 , 38 , 41 , 43 , 44 , 45 , 46 , 47 , 51 , 56 , 57 , 59 , 60 , 61 , 62 , 66 , 70 , 71 , 77 , 80 , 81 eight from Denmark, 35 , 39 , 48 , 69 , 74 , 76 , 79 , 82 seven from Spain, 19 , 30 , 34 , 40 , 49 , 63 , 65 five from the Netherlands, 50 , 52 , 53 , 54 , 64 five from Sweden, 67 , 68 , 78 , 83 , 84 four from Australia, 27 , 28 , 37 , 72 two from China, 32 , 55 one from the USA, 73 one from Canada, 42 one from New Zealand, 58 one from Egypt, 75 one from Italy, 36 one from Malaysia 33 and one from Nigeria. 29 For further...…”

“…If they had more than one symptom, they were attributed one in order of decreasing clinical importance: rectal bleeding, anaemia, diarrhoea, altered bowel habit, abdominal pain, and weight loss. (Oct 2013–March 2014) Median (IQR) = 64 (52–73) Range = 16–90 Analysed: Male = 342 Female = 413 NR Colonoscopy CRC = 28 HRA = 41 Nemlander 2023a 78 (Sweden) Case-control Primary Overall = 2681 Development = 2013 Validation = 668 Swedish cancer register and the VEGA regional administrative healthcare database. Dates NR Age at diagnosis date Mean (SD) Cases = 71.2 (11.7) Controls = 71.2 (11.7) Male Cases = 272/542 Controls = 1074/2139 I = 118 II = 278 III = 130 Registry Non-metastatic CRC Development = 407 Validation = 135 Nemlander 2023b 84 (Sweden) Case-control Primary Overall = 14,548 Stockholm regional health care administration database (VAL) 2015–2019 Age at diagnosis date Mean (SD) Cases = 70.7 (12.6) Controls = 70.6 (12.5) Male Cases = 1483/2920 Controls = 5901/11,628 I = 731 II = 846 III = 1343 Registry Non-metastatic CRC cases = 2920 Norrelund 1996 35 (Denmark) Cross-sectional Primary Study 1 = 208 Study 2 = 209 (analysis = 156) Study 1 Every fourth GP registered in the directory of the Danish medical associaton (n = 750) were to participate in the study.…”